A Global Product and Pipeline Analysis of Antiretroviral Drug Development for the Treatment of HIV/AIDS

Antiretroviral Combinations Continue to Transform the Treatment Landscape

Regular Price: USD 3,950

Special Price USD 3,555

10% OFF

* Required Fields

Regular Price: USD 3,950

Special Price USD 3,555

PAY BY INVOICE

Be the first to review this product

This research service focuses on antiviral/antiretroviral therapeutics for the treatment of HIV/AIDS. A product and pipeline assessment is provided for marketed and investigational products and combination regimens for the treatment of HIV infection. Segmentation by drug class is provided along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and global prevalence by region and country. Key market developments since Q1 2013 and key companies to watch are also included. This research service is an update of the 2013 research service titled Strategic Analysis of Antiviral Drug Development for Viral Hepatitis and HIV/AIDS.

Table of Contents

Executive SummaryKey Market Developments since Q1 2013Key FindingsEvolution of Standard of Care for HIVKey Companies to WatchMethodology and ScopeMethodology and ScopeIntroductionHIV Overview HIV Overview (continued)Prevalence of HIV/AIDS Globally and by RegionMarket Segmentation Market Segmentation (continued)HIV/AIDS Antiretroviral MarketHIV/AIDS Antiretroviral Market—Competitive Landscape ofMarketed ProductsHIV/AIDS Antiretroviral Market—Competitive Landscape ofProducts in DevelopmentHIV/AIDS Antiretroviral Market—Product Launch and Patent Expiration TimelineHIV/AIDS Antiretroviral Market—Major Phase 3 Ongoing TrialsHIV/AIDS Antiretroviral Market—Major Phase 3 Ongoing Trials (continued)HIV/AIDS Antiretroviral Market—Recent Pivotal Trial ResultsHIV/AIDS Antiretroviral Market—Recent Pivotal Trial Results (continued)Marketed Product Synopsis—Multi-class FDC ProductsMarketed Product Synopsis—Single-class FDC ProductsMarketed Product Synopsis—Single-entity ProductsMarketed Product Synopsis—Single-entity Products (continued)Marketed Product Synopsis—Single-entity Products (continued)Marketed Product Synopsis—Single-entity Products (continued)Marketed Product Synopsis—Single-entity Products (continued)Marketed Product Synopsis—Single-entity Products (continued)Marketed Product Synopsis—Single-entity Products (continued)Pipeline Synopsis—Late-stage Development ProductsPipeline Synopsis—Late-stage Development Products (continued)Pipeline Synopsis—Late-stage Development Products (continued)Pipeline Synopsis—Late-stage Development Products (continued)Pipeline Synopsis—Late-stage Development Products (continued) Pipeline Synopsis—Late-stage Development Products (continued)Pipeline Synopsis—Early Clinical Development ProductsPipeline Synopsis—Early Development ProductsPipeline Synopsis—Early Development Products (continued)Pipeline Synopsis—Early Development Products (continued)Conclusions and RecommendationsConclusions and Recommendations Legal DisclaimerAppendixDecision Support Database—Prevalence of HIV InfectionDecision Support Database—Prevalence of HIV Infection (continued)Decision Support Database—Prevalence of HIV Infection (continued)Decision Support Database—Prevalence of HIV Infection (continued)Decision Support Database—Prevalence of HIV Infection (continued)Decision Support Database—Prevalence of HIV Infection (continued)Decision Support Database—Prevalence of HIV Infection (continued)Decision Support Database—Prevalence of HIV Infection (continued)Decision Support Database—Prevalence of HIV Infection (continued)Decision Support Database—Prevalence of HIV Infection (continued)The Frost & Sullivan StoryThe Frost & Sullivan StoryValue Proposition: Future of Your Company & CareerGlobal PerspectiveIndustry Convergence360º Research PerspectiveImplementation ExcellenceOur Blue Ocean Strategy




Keyword1

Keyword2

Keyword3

Related Research

Release Date : 31-Oct-17

Region : Global

Release Date : 19-May-17

Region : Global

Release Date : 12-May-17

Region : Global

Release Date : 12-May-17

Region : Global

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.